Similar articles for PMID: 16080483

Year	Number of Results
1986	1
1993	1
1994	2
2004	4
2005	22
2006	21
2007	16
2008	12
2009	8
2010	2
2011	4
2012	3
2013	3
2014	2
2015	3
2016	5
2017	2
2018	3
2019	2
2021	1
2022	0

1

A practical overview of aromatase inhibitors.

Younus J, Vandenberg TA. Younus J, et al. Anticancer Res. 2005 May-Jun;25(3c):2497-502. Anticancer Res. 2005. PMID: 16080483 Free article. Review.

2

A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.

Younus J, Vandenberg TA. Younus J, et al. Bull Cancer. 2005 Apr;92(4):E39-44. Bull Cancer. 2005. PMID: 15888383 Free article. Review.

3

Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.

Singh Ranger G. Singh Ranger G. J Clin Pharm Ther. 2005 Aug;30(4):313-7. doi: 10.1111/j.1365-2710.2005.00655.x. J Clin Pharm Ther. 2005. PMID: 15985044 Review.

4

Endocrine therapy for early breast cancer.

Hussain SA, Williams S, Stevens A, Rea DW. Hussain SA, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):877-88. doi: 10.1586/14737140.4.5.877. Expert Rev Anticancer Ther. 2004. PMID: 15485321 Review.

5

Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

Wheler J, Johnson M, Seidman A. Wheler J, et al. Semin Oncol. 2006 Dec;33(6):672-80. doi: 10.1053/j.seminoncol.2006.08.018. Semin Oncol. 2006. PMID: 17145347 Review.

6

The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.

Poole R, Paridaens R. Poole R, et al. Curr Opin Oncol. 2007 Nov;19(6):564-72. doi: 10.1097/CCO.0b013e3282f1c523. Curr Opin Oncol. 2007. PMID: 17906453 Review.

7

Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.

Smith IE. Smith IE. Breast. 2004 Dec;13 Suppl 1:S3-9. doi: 10.1016/j.breast.2004.09.002. Breast. 2004. PMID: 15585377 Review.

8

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ. Mouridsen HT, et al. Eur J Cancer. 2005 Aug;41(12):1678-89. doi: 10.1016/j.ejca.2004.10.020. Epub 2004 Nov 25. Eur J Cancer. 2005. PMID: 16098456 Review.

9

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.

Mouridsen HT. Mouridsen HT. Curr Med Res Opin. 2006 Aug;22(8):1609-21. doi: 10.1185/030079906X115667. Curr Med Res Opin. 2006. PMID: 16870085 Review.

10

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

Spicer J, Ellis P. Spicer J, et al. Cancer Lett. 2007 Apr 18;248(2):165-74. doi: 10.1016/j.canlet.2006.07.002. Epub 2006 Aug 21. Cancer Lett. 2007. PMID: 16919870 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed